Buy Vafseo’s Approval: A New Chapter For Akebia Therapeutics In Anemia Management (AKBA)


Share post:

SewcreamStudio/iStock via Getty Images

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company specializing in anemia management due to chronic kidney disease [CKD]. Its drug, Vadadustat, known commercially as Vafseo, received FDA approval in March 2024 for adults on dialysis that could treat


Please enter your comment!
Please enter your name here

Related articles

Exploring MGA Funding Then and Now

This post is part of a series sponsored by...

How Stephen Regenold Grew His Site to 10 Million Monthly Views

Ready to hear how this journalist leveraged his content writing and industry experience to build a media...

Departing Boeing CEO Dave Calhoun cut his bonus in 2024 after the door plug flew off an Alaska Airlines flight

The Boeing board is pledging to get the airline manufacturer back on track, and new independent Chairman...

Beyond Black and White Logos, These Are the Emerging Design Trends to Watch 

It's not just black and white: Experts say design is moving away from minimalism and shifting to...